Breaking Finance News

A statement released earlier today by Citigroup Inc. about Kadmon Holdings Inc (NASDAQ:KDMN) bumps the target price to $12.00

In a report announced on 8/22/2016 Citigroup Inc. raised the target price of Kadmon Holdings Inc (NASDAQ:KDMN) from $0 to $12 indicating a possible upside of 0.20%.

Showing a price of $10.01, Kadmon Holdings Inc (NASDAQ:KDMN) traded 3.41% lower on the day. The last stock close is up 24.12% relative to the 200-day moving average, compared with the S&P 500 which has decreased -0.01% over the same time. Kadmon Holdings Inc has logged a 50-day moving average of $9.71 and two hundred day moving average of $9.71. 43,003 shares of KDMN were exchanged, down from ann avg. trading volume of 103,248

Performance Chart:

Kadmon Holdings Inc (NASDAQ:KDMN)

Kadmon Holdings Inc has a 52 week low of $7.29 and a one-year high of $10.48 . Kadmon Holdings Inc’s total market value is presently $0.0.

About Kadmon Holdings Inc (NASDAQ:KDMN)

Kadmon Holdings, Inc., formerly Kadmon Holdings, LLC, is a biopharmaceutical company, which is engaged in the discovery, development and commercialization of small molecules and biologics. The Company is developing product candidates within autoimmune and fibrotic diseases, oncology and genetic diseases. The Company offers KD025, Tesevatinib in Oncology, Tesevatinib in polycystic kidney disease (PKD) and KD034. It offers tablets and capsules, such as Ribasphere RibaPak, Ribasphere tablets, Ribasphere, Qsymia, Tetrabenazine and Valganciclovir. KD025 is its candidate in its rho-associated coiled-coil kinase 2 (ROCK2) platform, which is an oral, selective ROCK2 inhibitor. Tesevatinib is an oral tyrosine kinase inhibitor (TKI) designed to block molecular drivers of tumor growth, metastases and drug resistance. KD034 is its portfolio of formulations of trientine hydrochloride, a chelating compound for the removal of excess copper from the body, and for the treatment of Wilson’s disease.

Receive News & Ratings Via Email - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings with's FREE daily email newsletter.

Leave a Reply

Your email address will not be published. Required fields are marked *